Loading data...
Platform Section Title Presenter City Country
PL001 Brain Tumors/Oncology Biomarkers of CAR T cell neurotoxicity: CSF NFL and GFAP in an expansion cohort of pediatric ALL patients Juliane Gust Seattle United States
PL002 Brain Tumors/Oncology Impact of Molecular Subgrouping on Event-Free Survival (EFS): Results of a Children’s Oncology Group (COG) Randomized Trial for Children with Medulloblastoma (MB); COG-ACNS 0331 Roger Packer Washington United States
PL003 Cognitive/Behavioral Disorders (including Autism) Clinical profile of children presenting with functional neurological complaints from a tertiary care center in north India Sheffali Gulati New Delhi India
PL004 Cognitive/Behavioral Disorders (including Autism) Increased Autoimmune Disease in Mothers of Children with Tourette Syndrome and Obsessive-Compulsive Disorder Hannah Jones Sydney Australia
PL005 Cognitive/Behavioral Disorders (including Autism) The relationship between parental stress and mastery, forgiveness, and social support among parents of children with autism in a collectivistic and an individualistic society Muhammad Mahajnah Hadera Israel
PL006 Critical Care Prevalence of Prognostic Discordance for Infants in the Intensive Care Unit Sarah Bernstein Durham United States
PL007 Demyelinating Disorders Interim results from phase 2/3 (ALD-102) and phase 3 (ALD-104) studies of elivaldogene autotemcel (Lenti-D) gene therapy for the treatment of cerebral adrenoleukodystrophy Florian Eichler Boston United States
PL008 Demyelinating Disorders Development of the PedsQL™ Multiple Sclerosis Module items: Focus group and cognitive interviews Cristina Gaudioso St. Louis United States
PL009 Demyelinating Disorders Pediatric MOG antibody-associated syndromes: Description of a novel neuroimaging pattern Sylvia Tenembaum Buenos Aires Argentina
PL010 Demyelinating Disorders Use of disease-modifying therapies in paediatric relapsing remitting multiple sclerosis in the UK: A multi-centre retrospective study Omar Abdel Mannan London United Kingdom
PL011 Epilepsy Time to Onset of Cannabidiol (CBD) Treatment Effect and Resolution of Adverse Events in the Tuberous Sclerosis Complex (TSC) Phase 3 Randomized Controlled Trial (GWPCARE6) Charuta Joshi Aurora United States
PL012 Epilepsy Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome (LGS): 3-Year Results of an Open-Label Extension (OLE) Trial (GWPCARE5) Anup Patel Columbus United States
PL013 Epilepsy Preventive antiepileptic treatment in infants with Tuberous Sclerosis Complex delays seizure onset and reduces epilepsy incidence and severity in a multi-center, randomized and observational EPISTOP trial Katarzyna Kotulska Warsaw Poland
PL014 Epilepsy Oligonucleotide STK-001 for the treatment of Dravet Syndrome: Cross-species pharmacology and efficacy in a mouse disease model Barry Ticho Bedford United States
PL015 Epilepsy Bridging the Childhood Epilepsy Treatment Gap in Africa (BRIDGE): A Protocol for a Cluster Randomized Clinical Trial of Task-Shifted Epilepsy Care in Three Northern Nigerian Cities Edwin Trevathan Nashville United States
PL016 Epilepsy Diagnostic and prognostic utility of outpatient short term video EEG records in children with seizures: experience from a tertiary care center in north India. Prateek Panda Rishikesh India
PL017 Epilepsy Epilepsy with Myoclonic Atonic Seizures (Doose Syndrome): A Severe Epileptic Encephalopathy with a Positive Outlook? Katherine Nickels Rochester United States
PL018 Epilepsy Electroclinical spectrum of childhood epilepsy secondary to neonatal hypoglycemic brain injury in a low resource setting: A 10 year experience Bijoy Patra Delhi India
PL019 Epilepsy Provider attitudes toward sexual and reproductive healthcare for young women with epilepsy and intellectual disabilities Laura Kirkpatrick Pittsburgh United States
PL020 Epilepsy Role of immunotherapy in children with new onset refractory status epilepticus (NORSE): Hit early and hit hard. Harshkumar Patel Ahmedabad India
PL021 Epilepsy Update on a sponsored no-cost epilepsy gene panel for seizure onset between 2–4 years of age: Results from 682 tests Tiffany Pang Novato United States
PL022 Epilepsy Management practices for West syndrome in South Asia: a survey study and meta-analysis Priyanka Madaan Chandigarh India
PL023 Epilepsy Hemodynamic responses to interictal epileptiforme discharges and clinical prognosis in childhood epilepsy with centrotemporal spikes Ana Carolina Coan Campinas Brazil
PL024 Epilepsy Perspectives on Preferred Practices for Rescue Therapies in Epilepsy: Gaps or Agreement? Patricia Shafer Wilmington United States
PL025 Epilepsy Medically intractable myoclonic epilepsy, intellectual disability, and dysmorphism in a teenage girl caused by a novel variant in NEXMIF Isabella Herman Houston United States
PL026 Epilepsy High dose diazepam treatment for Electrical Status Epilepticus in Sleep (ESES): Is it effective? Carolina Gorodetsky Toronto Ontario
PL027 Epilepsy Thalamocortical Loop Models as an Integrative Framework for Epileptiform Activity. Andrew Knox Madison United States
PL028 Epilepsy Efficacy of Combined Therapy of ACTH plus Vigabatrin compared to ACTH alone for treatment of Infantile Spasm- A Randomized controlled trail Samsun Sumi Dhaka Bangladesh
PL029 Epilepsy Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid Nancy McNamara Ann Arbor United States
PL030 Epilepsy Long-Term (2-Year) Safety and Efficacy of Adjunctive ZX008 (Fenfluramine Hydrochloride Oral Solution) for Dravet Syndrome: Interim Results of an Ongoing Open- Label Extension Study Joseph Sullivan San Francisco United States
PL031 Epilepsy Number Needed to Treat (NNT) With Fenfluramine to Achieve a Clinically Meaningful Reduction in Convulsive Seizure Frequency in Patients With Dravet Syndrome Joseph Sullivan San Francisco United States
PL032 Epilepsy POTENTIAL MECHANISMS OF SUDEP IN MOUSE MODEL OF ALTERNATING HEMIPLEGIA OF CHILDHOOD Courtney Elliott Chapel Hill United States
PL033 Epilepsy Improving folate supplementation counseling for adolescent females with epilepsy. Sara Fridinger Philadelphia United States
PL034 Epilepsy Worldwide short course education programmes in paediatric epilepsies – improving knowledge and changing attitudes and practice. Alison Gifford Dundee United Kingdom
PL035 Epilepsy Neuroimaging for Non-Index Seizures in Pediatric Emergency Rooms Emma Mazzio Denver United States
PL036 Epilepsy Decision-Making for Infants with Neurologic Conditions Charlotte Gerrity Durham United States
PL037 Epilepsy The expressions of microRNAs in febrile seizure Kursat Carman Eskisehir Turkey
PL038 Genetics Episodic hemiplegia secondary to channelopathies: clinical spectrum and genotype- phenotype correlations Daniel Calame Houston United States
PL039 Genetics Variability in diagnostic yield of exome sequencing by clinical phenotype: Review of 977 cases from a single center Cameron Crockett St. Louis United States
PL040 Genetics Pediatric 50K (P50K) Heredigene Project: Whole Genome Sequencing Initiative for 50,000 Children: Integrating Genomic Testing and Data with Longitudinal Pediatric Clinical Outcomes and Treatments in an Integrated Healthcare System Josh Bonkowsky Salt Lake City United States
PL041 Genetics Human Genetic Risk and Protective Factors In Congenital Zika Syndrome Youssef Kousa Washington United States
PL042 Genetics Characterization of PTEN-associated cortical malformations and associated clinical phenotype Diane Shao Boston United States
PL043 Genetics Diagnostic yield of genetic testing in infants with congenital hypotonia Sonal Sharma Kansas City United States
PL044 Infections/Neuroimmunology Common autoantigen identified in a cohort of ROHHAD-NET patients, supporting ROHHAD as a novel paraneoplastic neurological disorder Caleigh Mandel-Brehm San Francisco United States
PL045 Infections/Neuroimmunology Think AFM: many patients with acute flaccid myelitis are misdiagnosed Leslie Hayes Boston United States
PL046 Infections/Neuroimmunology Validity of the clinical diagnostic criteria for anti-N-methyl-D-aspartate receptor encephalitis in Japanese pediatric patients Hiroya Nishida Tokyo Japan
PL047 Infections/Neuroimmunology Comparison of Seizure Type and EEG findings in Autoimmune Encephalitis: A Multicenter Sample Annie Hong New Hyde Park United States
PL048 Infections/Neuroimmunology Clinico-radiological profile of children with acute necrotizing encephalopathy of childhood(ANEC) associated with dengue fever: A case series Harshkumar Patel Ahmedabad India
PL049 Infections/Neuroimmunology GAD65 Antibody Encephalitis presenting as treatment resistant temporal lobe epilepsy and peripheral neuropathy in a pediatric patient Maryam Nabavi Nouri London Ontario
PL050 Infections/Neuroimmunology Acute Encephalitis in the Pediatric Population of Western Pennsylvania Meghan Mack Pittsburgh United States
PL051 Movement Disorders (including Cerebral Palsy) The effect of intrathecal baclofen in dyskinetic cerebral palsy (IDYS trial): a multi-centre, randomised, double-blind, placebo-controlled trial Laura Bonouvrie Amsterdam Netherlands
PL052 Movement Disorders (including Cerebral Palsy) Stereotypies have lower burden of comorbidity compared to tics Shannon Dean Baltimore United States
PL053 Movement Disorders (including Cerebral Palsy) Anxiety symptoms in youth with and without tic disorders Jennifer Vermilion Rochester United States
PL054 Movement Disorders (including Cerebral Palsy) Improved Motor Function in Children With AADC Deficiency Treated with Eladocagene Exuparvovec (PTC-AADC): Interim Findings from a Phase 2 Trial Yin-Hsiu Chien Taipei City Taiwan
PL055 Movement Disorders (including Cerebral Palsy) High-throughput Screen For Small Molecules That Modulate Protein Trafficking In Adaptor Protein Complex 4 (AP-4) Associated Hereditary Spastic Paraplegia Darius Ebrahimi-Fakhari Boston United States
PL056 Movement Disorders (including Cerebral Palsy) Improved Motor Function in Children With AADC Deficiency Treated With Eladocagene Exuparvovec (PTC-AADC): Compassionate Use Study Paul Wuh-Liang Hwu Taipei City Taiwan
PL057 Neonatal & Fetal Neurology Lateralized neonatal EEG response to maternal voice exposure as a predictor of language outcome Renee Shellhaas Ann Arbor United States
PL058 Neonatal & Fetal Neurology Duration of Anti-seizure Medication Treatment and 2-Year Outcome After Acute Symptomatic Neonatal Seizures – a Neonatal Seizure Registry study Hannah Glass San Francisco United States
PL059 Neonatal & Fetal Neurology Short-Term Seizure Recurrence In Neonates With Acute Symptomatic Seizures: Early Vs Late Discontinuation Of Anti-epileptic drugs: A Randomized, Controlled, Non-Inferiority Trial Ramesh Konanki Hyderabad India
PL060 Neonatal & Fetal Neurology Effect of therapeutic hypothermia and pattern of injury on neurodevelopmental outcomes at 1-2 years in a prospective cohort of neonatal encephalopathy Ashley Bach San Francisco United States
PL061 Neonatal & Fetal Neurology Placental abnormalities in a large cohort of neonatal hypoxic-ischemic encephalopathy (HIE) Amy Goodman San Francisco United States
PL062 Neonatal & Fetal Neurology Advanced genetic analysis in fetuses and term neonates with idiopathic cerebral hemorrhage Moran Hausman-Kedem Tel-Aviv Israel
PL063 Neonatal & Fetal Neurology Hyperglycemia in term neonatal encephalopathy associated with increased risk for neonatal seizures Carlos Salazar Toronto Ontario
PL064 Neurometabolic Disorders Persistent treatment effect of cerliponase alfa in children with CLN2 disease: A >4 year update from an ongoing multicenter extension study Angela Schulz Hamburg Germany
PL065 Neurometabolic Disorders Reduction of Rate of Severity Increment in a Cohort of Patients with Niemann-Pick Type C1 (NPC1) Treated Long-Term With Intrathecal Adrabetadex Elizabeth Berry-Kravis Chicago United States
PL066 Neurometabolic Disorders Development of the “Hamburg Best Practice Guidelines for intracerebroventricular (ICV)- enzyme replacement therapy (ERT) in CLN2 Disease” based on 5 years treatment experience in 48 patients Christoph Schwering Hamburg Germany
PL067 Neurometabolic Disorders Single-dose AAV9-CLN6 gene transfer stabilizes motor and language function in CLN6- type Batten disease: interim results from the first clinical gene therapy trial Emily de los Reyes Columbus United States
PL068 Neuromuscular Disorders Increased intracranial pressure in pediatric patients with Spinal Muscular Atrophy receiving nusinersen via lumbar puncture Stephanie Acord Fortworth United States
PL069 Neuromuscular Disorders Ataluren delays loss of ambulation and decline in pulmonary function in patients with nmDMD Craig McDonald Sacramento United States
PL070 Neuromuscular Disorders Onasemnogene Abeparvovec-xioi Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1): Phase 3 Study Clinical Update (STR1VE-EU) Eugenio Mercuri Rome Italy
PL071 Neuromuscular Disorders Nusinersen in Infantile-onset Spinal Muscular Atrophy: Results from Longer-term Treatment from the Open-label SHINE Extension Study Boris Kandinov Cambridge United States
PL072 Neuromuscular Disorders Nusinersen in advanced-stage patients with spinal muscular atrophy type1. Katarzyna Kotulska Warsaw Poland
PL073 Neuromuscular Disorders One-Time Administration of AVXS-101 IT for Spinal Muscular Atrophy: Phase 1/2 Study (STRONG) Richard Finkel Orlando United States
PL074 Neuromuscular Disorders Longer-term Nusinersen Treatment According to Age at First Dose: Results From the SHINE Study in Later-onset Spinal Muscular Atrophy (SMA) Basil Darras Boston United States
PL075 Neuromuscular Disorders Pulmonary function in non-ambulatory patients with nmDMD: Strategic Targeting of Registries and International Database of Excellence (STRIDE) Registry and CINRG DNHS matched cohort analysis Andrés Nascimento Osorio Barcelona Spain
PL076 Neuromuscular Disorders Beyond the Muscle: The Expanding Mutational and Phenotypic Spectrum of Disease Due to Mutations in the MICU1 gene (mitochondrial calcium uptake 1) Shanawaz Hussain Leeds United Kingdom
PL077 Neuromuscular Disorders Onasemnogene Abeparvovec-xioi Gene Therapy in Presymptomatic Spinal Muscular Atrophy: SPR1NT Study Update Kevin Strauss Strasburg United States
PL078 Neuromuscular Disorders Nusinersen Effect in Infants Who Initiate Treatment in a Presymptomatic Stage of SMA: NURTURE Results Darryl De Vivo New York United States
PL079 Neuromuscular Disorders Long-Term Follow-Up of Onasemnogene Abeparvovec-xioi Gene Therapy in Spinal Muscular Atrophy Type 1 (SMA1) Jerry Mendell Columbus United States
PL080 Neuromuscular Disorders Georgia state SMA newborn screening (NBS) pilot: clinical outcomes and way forward Kathryn Elkins Atlanta United States
PL081 Neuromuscular Disorders Intravenous (IV) Onasemnogene Abeparvovec-xioi Clinical Development Programs in Spinal Muscular Atrophy (SMA): Integrated Safety Report Deepa Chand Bannockburn United States
PL082 Neuromuscular Disorders Edasalonexent Treatment in Young Boys with Duchenne Muscular Dystrophy is Associated with Age-Normative Growth and Normal Adrenal Function Erika Finanger Portland United States
PL083 Neuromuscular Disorders Systemic Gene Transfer with rAAVrh74.MHCK7.SGCB Increased β-sarcoglycan Expression in Patients with Limb Girdle Muscular Dystrophy Type 2E (LGMD2E) Louise Rodino-Klapac Cambridge United States
PL084 Neuromuscular Disorders Systemic Gene Transfer with rAAVrh74.MHCK7.micro-dystrophin in Patients with Duchenne Muscular Dystrophy Jerry Mendell Columbus United States
PL085 Neurorehabilitation Development and Evaluation of a low-cost working memory intervention kit for cognitive deficits in children with epilepsy: a pilot study Aakanksha Anand New Delhi India
PL086 Neurorehabilitation Efficacy of abobotulinumtoxinA in reducing upper-limb spasticity in children with cerebral palsy: Results from a Phase 3, pivotal study Ann Tilton New Orleans United States
PL087 Neuroscience Dysfunction of D2 dopamine receptor neurons underlies select manic-like behaviors in SHANK3 overexpressing mice J. Holder, Jr. Houston United States
PL088 Rare Diseases The natural history of fatty acid hydroxylase-associated neurodegeneration (FAHN). Sunita Venkateswaran Ottawa Ontario
PL089 Rare Diseases Efficacy and safety of arimoclomol in patients with Niemann Pick Type C: Results from a double-blind, randomised placebo-controlled trial with a novel treatment Marc Patterson Rochester United States
PL090 Stroke (including other Vascular Disorders) Harnessing Multimodal Neuroimaging to Predict Higher-Order Language Outcome Post Neonatal Stroke: An In Vivo Model of Neuroplasticity Zahra Emami Toronto Ontario
PL091 Stroke (including other Vascular Disorders) Robotic sensorimotor assessment of children with perinatal stroke and hemiparesis following intensive motor learning and neuromodulation Lauran Cole Calgary Alberta
PL092 Stroke (including other Vascular Disorders) Regional thalamic dysrhythmia and connectivity abnormalities relate to motor performance in children with perinatal stroke Anton Rogachov Toronto Canada
PL093 Stroke (including other Vascular Disorders) Posterior Choroidal Artery Collaterals Predict Ischemic Event Recurrence and Response to Revascularization Surgery in Childhood Moyamoya Matsanga Leyila Kaseka Toronto Ontario
PL094 Stroke (including other Vascular Disorders) Perinatal infections: an important etiological risk factor for Mineralizing angiopathy in children Mahesh Kamate Belagavi India
PL095 Stroke (including other Vascular Disorders) Intracranial and extracranial vascular stenosis as risk factors for stroke in sickle cell disease Alyssa Schlotman Nashville United States
PL096 Stroke (including other Vascular Disorders) Cerebral venous sinus thrombosis in infants after surgery for congenital heart disease Dana Harrar Washington United States
PL097 Teaching of Child Neurology Quality Improvement Measures in an Academic Pediatric Neurology Outpatient Practice Stephanie Enner Queens United States
PL098 Teaching of Child Neurology Adoption of Telemedicine within Pediatric Neurology of the MGH Healthcare System before and during the COVID-19 Pandemic Albert Misko Boston United States
PL099 Translational/Experimental Therapeutics Transpher A, an open-label, multicenter, single-dose, dose-escalation, Phase 1/2 Clinical Trial of gene transfer of ABO-102 in Sanfilippo Syndrome type A (Mucopolysaccharidosis IIIA): Safety, tolerability, biopotency and neurocognitive data Kevin Flanigan Columbus United States
PL100 Trauma Cerebral blood flow predicts outcome in children with persistent post-concussion syndrome Karen Barlow Brisbane Australia
Platform Section Title Presenter City Country
Like
Like
Happy
Love
Angry
Wow
Sad
0
0
0
0
0
0